You've reached the limit for free Overall Ranking scores. For more information, request a demo.
See CSRHub in Action
You have a total of 10 free searches available.
| Low 0-29 | 30-39 | 40-49 | 50-59 | 60-79 | 80-100 High |
Cell Genesys is a South San Francisco-based biotechnology company. Since its inception, the company focused primarily on the development and commercialization of novel biological therapies for patients with cancer. In August 2008 and October 2008, the company terminated its two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer and subsequently placed on hold the further development of this program and implemented a substantial restructuring of business operations. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders.
On June 30th, 2009, BioSante announced entering into a definitive merger agreement with Cell Genesys (CEGE) in an all-stock transaction, with BioSante as the surviving company.
| Ticker: | CEGE |
| ISIN: | US1509211041 |
| Address: |
500 Forbes Boulevard |
| South San Francisco, CA, 94080, USA | |
| Website: | Cell Genesys, Inc. |
| Phone #: | 650-2663000 |
| ESG Web Area: | Subscribers Only ? |
| Industry: | Biotechnology |
We considered many names for our site—in fact we spent our first year and a half under a different name—EkoHub. We liked “Eko” — coming from the Greek word Oikos, related to economy, ecology, and “home” or social concerns. From the beginning, we believed the word “Hub” reflected our desire to be at the center of the sustainability area, providing knowledge, harmony, and consensus among the hundreds of experts judging the ESG performance of companies.